• Users Online: 136
  • Print this page
  • Email this page


 
 Table of Contents  
REVIEW ARTICLE
Year : 2017  |  Volume : 7  |  Issue : 2  |  Page : 62-69

Pharmacological therapy for amblyopia


Department of Ophthalmology, All Institute of Medical Sciences, Rishikesh, Uttarakhand, India

Date of Submission06-May-2016
Date of Acceptance02-Oct-2016
Date of Web Publication20-Jun-2017

Correspondence Address:
Anupam Singh
Department of Ophthalmology, All India Institute of Medical Sciences, Rishikesh - 249 203, Uttarakhand
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/tjo.tjo_8_17

Get Permissions

  Abstract 

Amblyopia is the most common cause of preventable blindness in children and young adults. Most of the amblyopic visual loss is reversible if detected and treated at appropriate time. It affects 1.0 to 5.0% of the general population. Various treatment modalities have been tried like refractive correction, patching (both full time and part time), penalization and pharmacological therapy. Refractive correction alone improves visual acuity in one third of patients with anisometropic amblyopia. Various drugs have also been tried of which carbidopa & levodopa have been popular. Most of these agents are still in experimental stage, though levodopa-carbidopa combination therapy has been widely studied in human amblyopes with good outcomes. Levodopa therapy may be considered in cases with residual amblyopia, although occlusion therapy remains the initial treatment choice. Regression of effect after stoppage of therapy remains a concern. Further studies are therefore needed to evaluate the full efficacy and side effect profile of these agents.

Keywords: Amblyopia, levodopa, pharmacological therapy for amblyopia


How to cite this article:
Singh A, Nagpal R, Mittal SK, Bahuguna C, Kumar P. Pharmacological therapy for amblyopia. Taiwan J Ophthalmol 2017;7:62-9

How to cite this URL:
Singh A, Nagpal R, Mittal SK, Bahuguna C, Kumar P. Pharmacological therapy for amblyopia. Taiwan J Ophthalmol [serial online] 2017 [cited 2017 Nov 20];7:62-9. Available from: http://www.e-tjo.org/text.asp?2017/7/2/62/207437


  Introduction Top


Amblyopia is defined as unilateral or bilateral dimness of vision caused by form vision deprivation and/or abnormal binocular interaction.[1] This is the most common cause of preventable monocular blindness in children and young adults.[2] Amblyopic visual loss is reversible with timely detection and appropriate intervention in almost all cases.[3] Various treatment modalities such as refractive correction,[4],[5],[6],[7],[8] patching,[9],[10],[11],[12],[13],[14],[15],[16],[17],[18],[19],[20],[21] penalization,[22],[23],[24],[25],[26],[27],[28],[29],[30],[31],[32] and pharmacological therapy [33],[34],[35],[36],[37],[38],[39],[40],[41],[42] have been tried till date.

Various drugs have been tried, of which carbidopa and levodopa have been popular. The past efforts to treat amblyopia medically have experimented with substances such as oxygen, strychnine, alcohol, propranolol, bicuculline, and exogenous nerve growth factor (NGF), but none were successful in terms of clinical applicability and effectiveness.


  Pharmacological Therapy Top


The conventional occlusion therapy for amblyopia is often found incomplete as many patients are left with some amount of permanent reduction in visual acuity (VA) despite maintaining adequate compliance.[43],[44],[45],[46] In view of this suboptimal response, alternative treatment options are being tried such as levodopa-carbidopa combination, antidepressants such as fluoxetine, GABA antagonists, and cytidine 5'-diphosphocholine (CDP).

Levodopa-carbidopa combination therapy

It is a well-known theory that amblyopia is a consequence of competition between individual eye's input to the visual cortical cells. This phenomenon of binocular competition, besides age, has been shown to be dependent on the presence of certain neurotransmitters and neuromodulators in the brain.[47],[48],[49],[50]

Kasamatsu and Pettigrew [49] in an animal study showed that even older amblyopic animals could recover some function if their brain is flooded with a dopaminergic drug. The study also found that the adverse effects of occlusion could be prevented, if a neurotoxin such as 6-hydroxydopamine is administered to destroy the dopaminergic terminals, suggesting that dopaminergic drugs may influence visual cortical plasticity and hence visual recovery in the amblyopes.

Oral levodopa is used to supplement dopamine deficiency in adults with Parkinson's disease and children with dopamine-responsive dystonias. Levodopa-carbidopa combination therapy has been used for the treatment of amblyopia since 1993.[51],[52] Dopamine has been known to play an important role in retinal function and in central visual processing.[43],[44],[45],[46],[47],[48],[49],[50],[51],[52],[53] Dopamine cannot be administered as such since it is unable to cross blood–brain barrier. Levodopa is a precursor of dopamine, and easily crosses blood–brain barrier. Carbidopa is a peripheral decarboxylase inhibitor which prevents peripheral conversion of levodopa to dopamine, thereby increasing the availability of levodopa in the central nervous system and allowing for reduction in the dose by about 75%.[52],[53],[54]

Levodopa has been shown to improve VA and visual-evoked potential (VEP) amplitudes in various studies in amblyopic patients [Table 1]. Various doses of levodopa have been tried for different durations: single-dose,[38] 1-week,[55] 3-week,[51] and 7-week course.[56],[57],[58] Some studies used lower doses – 1.5 mg/kg/day [39],[56],[57],[58] and 30 mg/day [51] of levodopa – while others used higher ones – 6–13 mg/kg/day.[38],[55],[59] Levodopa has also been used for management of residual amblyopia after failure of other therapies and in older age group up to 46 years.[60],[61],[62],[63] Despite initial improvement in VA, partial regression has been seen to occur after stopping the medication.[38],[55],[64]
Table 1: Outcomes of oral levodopa/carbidopa combination therapy for the management of amblyopia

Click here to view


Levodopa is usually administered along with carbidopa in a 4:1 dose ratio, either in the form of oral tablets or as oral suspension. Liquid suspensions have been shown to be stable for around 28 days when stored at 25°C and for 42 days, when stored at 4°C.[65] The drug is bitter in taste and therefore advised to use it with a protein drink.[66],[67] Overall, levodopa has been shown to be well tolerated in children.[47] Leguire et al.[60] found that continuous use of levodopa/carbidopa therapy (1.02/0.25 mg/kg body weight) lowered oral body temperature by 1.2°F over a 7-week period. Hence, it has been suggested that longitudinal oral dosing with levodopa should be <1.02 mg/kg body weight three times daily, to prevent change in body temperature. Other commonly reported side effects include headache, nausea, dry mouth, and abdominal cramps.[43],[46]

Effects of levodopa administration

Increased endogenous expression of nerve growth factor

Li et al.[67] assessed the anatomic and physiologic effects of L-DOPA methyl ester administration on visual cortex area 17 in a feline model with stimulus deprivation amblyopia. The structural changes and the expression of NGF were studied using immunohistochemical staining and Western blot. The study found significantly increased the density of NGF-immunoreactive cells and elevated expression of endogenous NGF in the visual cortex following drug administration.

Expression of N-methyl-D-aspartate receptor-1-subunit in the visual cortex

Zhao and Shi showed the importance of glutamate and its receptor N-methyl-D-aspartate receptor-1-subunit (NMDAR1) in the pathogenesis of amblyopia.[68] NMDAR1 is known to improve the permeability of nerve cells for calcium ions leading to intracellular physiological changes. NMDAR1 regulates the plasticity during the critical and adult period.[69] Studies have shown reduced expression of NMDAR1 in visual cortical neurons in amblyopic animals compared to the controls.[70],[71] In another study by Sun and Zhang,[72] the expression of NMDAR1 in the visual cortex of monocularly deprived rats was studied before and after administering levodopa. The study found increased expression of NMDAR1 protein and mRNA in the group that received levodopa, suggesting that NMDAR1 could be related to the plasticity of visual development and levodopa might reverse its expression in the visual cortex.

Improved visual-evoked potential response

Den et al.[73] evaluated the effects of single dose of levodopa administration on pattern VEP (PVEP) in cases with unilateral amblyopia. The study found decreased latency of N1 and P1 in the amblyopic eye and increased amplitude of N1P1 and P1N2 in the sound eye. In another study done by Basmak et al.,[56] the efficacy of levodopa administration, thrice a day for 1 week, was studied in 32 amblyopic children, aged 4 and 17 years with central fixation. After 1 week, a significant but transient improvement in VA and PVEP amplitudes was noted.

Visual field changes

Gottlob et al.[74] studied VA and visual field changes at 3 weeks, 1 month, and 2 months of daily administration of levodopa/carbidopa combination therapy. The study found a significant increase in VA and a decrease in fixation point scotomas, which persisted for around 2 months after completion of treatment.

Functional magnetic resonance imaging changes

Algaze et al.[75] used functional magnetic resonance imaging (fMRI) to assess differences between amblyopic and normal adults. They found that the level and extent of activation of occipital visual cortex elicited by stimulation of the amblyopic eye was less than that of the dominant eye. The area of activation driven by monocular stimulation of the amblyopic eye was about 50% less than that of the dominant eye. Amblyopes exhibited a significantly larger interocular difference in activation compared to normals. The study found fMRI, a potential tool for the assessment of human amblyopia.

In another randomized study by Rogers,[47] the effects of single dose of levodopa administration (2 mg/kg body weight) on visual cortex and visual functions were studied using fMRI and psychophysical tests, in 6 amblyopic and 9 normal subjects at baseline and at 90 min the administration. The parameters analyzed were the area and level of activation and a summed score (area × level). At baseline, the area of activation and summed score were significantly less in the amblyopic eyes compared to the dominant ones. Following levodopa ingestion, VA showed significant improvement along with a decrease in the area and level of activation with levodopa administration suggesting only a weak correlation between VA and fMRI changes in amblyopia.

Outcomes of oral levodopa/carbidopa combination therapy for management of amblyopia in various studies are summarized [Table 1].

Fluoxetine

Fluoxetine is a selective serotonin reuptake inhibitor, used as antidepressant. It acts by altering the cortical expression of various heat shock proteins and neurofilaments which are important for synaptic functions. Guest et al. demonstrated an increase in the percentage of synapses with split postsynaptic densities, a phenomenon characteristic of activity-dependent synaptic rearrangement on electron microscopic analysis.[76] Maya Vetencourt et al. showed that chronic administration of fluoxetine promotes the recovery of visual functions in adult amblyopic animals by reducing the intracortical inhibition and increasing the expression of brain-derived neurotrophic factor in the visual cortex, both of which are prevented by cortical administration of diazepam.[77]

Fluoxetine can have various side effects such as irritability, behavioral changes, restlessness, and agitation. This drug should be prescribed with caution in patients with impaired liver and renal function, in case of diabetes and bipolar disorders.

GABA antagonists

Monocularly deprived experimental animals have been shown to have lack of responsiveness to visual stimulation of the deprived eye. Various experimental studies have been conducted to establish the possible etiology.

Duffy et al.[78] evaluated various agents to reverse the effects of monocular deprivation including GABA antagonists such as bicuculline, picrotoxin, and naloxone, glycine antagonist such as strychnine, chloride channel blockers such as ammonium ion and cholinesterase inhibitor, physostigmine. The drugs were administered through intravenous route. The study found that drugs with GABA antagonistic action were effective in restoring neuronal responsiveness in the deprived eye. Bicuculline restored binocularity in 50% of the visual cortical neurons tested and naloxone in up to 36% neurons. The receptive fields of both eyes were found normal after the drug administration. Ammonium ion also restored binocularity in 27% of neurons tested, but with grossly abnormal receptive fields. Other agents including strychnine and physostigmine failed to restore binocularity. The study concluded that GABA inhibition may contribute to the cortical effects since only the drugs with GABA antagonistic activity were able to restore binocularity.

In another experimental study done by Burchfiel and Duffy,[79] involving 4 monocularly deprived cats, GABA antagonist, bicuculline was administered microiontophoretically in the cells present in the visual cortex at 5 months of age. The study found that bicuculline was able to restore input in 42% of cells in the deprived eye.

Mower et al.[80] also studied the role of microiontophoretic application of bicuculline in rearing cats with surgically induced strabismus and found that the agent was able to restore binocular responses in over 50% of monocularly deprived cells.

Various side effects are reported with this group of drugs. For example, bicuculline can cause behavioral changes, and ammonium ions can impair renal and hepatic function. Further, naloxone can be associated with severe allergic reaction and opiod withdrawal symptoms such as nausea, vomiting, diarrhea, running nose, tremor, shivering, and tachycardia. Physostigmine can cause seizure, cardiovascular collapse, bradycardia, bronchospasm, dyspnea, diaphoresis, diarrhea, hyperperistalsis, and hallucinations.

Cytidine 5'-diphosphocholine, CDP-choline, or citicoline

Citicoline is an intermediate by-product involved in the biosynthesis of cell membrane phospholipids. Following systemic administration, it gets degraded into its constituents, cytidine and choline. Citicoline, once absorbed, crosses the blood–brain barrier and gets incorporated into the cell membrane phospholipids. It has been shown to increase the levels of norepinephrine and dopamine levels in CNS, offering neuroprotection in hypoxic and ischemic conditions. In addition, citicoline has been shown to restore the activity of mitochondrial ATPase and membrane Na +/K + ATPase, thereby accelerating resorption of cerebral edema in various experimental models. It has been shown to inhibit apoptosis in neurodegenerative models, thereby potentiating neuroplasticity. Based on these neuromodulatory properties, it may prove beneficial in ocular conditions such as amblyopia and glaucoma. Organic brain disorders such as cerebral vascular disease, head trauma, cognitive disorders, posttraumatic coma and neurological deficits, postconcussional syndrome, acute ischemic cerebral vascular disease, senile cognitive impairment secondary to degenerative diseases and chronic cerebral vascular diseases, Parkinson disease, and drug addictions might also benefit from the chronic use of this drug. The drug is well tolerated with no significant systemic cholinergic effects.[81] However, some patients can have side effects such as insomnia, headache, diarrhea, low or high blood pressure, and nausea.

Porciatti et al.[82] measured contrast sensitivity and VEPs in amblyopic patients before and after the administration of CDP-choline (1 g/day intramuscular injection for 15 days) and the day after stopping treatment. The study found improvement in VA, contrast sensitivity, and VEP amplitudes in both normal and amblyopic eyes. Campos et al.[83] also reported a statistically significant improvement in VA following treatment with citicoline (1000 mg intramuscular administration, daily for 15 days) in older children, and found that significant visual improvement occurred in both amblyopic and sound eye, which remained stable for at least 4 months after stopping the treatment.


  Conclusion Top


The inadequacy of conventional occlusion treatment therapy and noncompliance of patients led to an insight into the role of pharmacological therapy for the management of amblyopia. Various studies have shown improvement in VA and VEP amplitudes with these agents in amblyopic children. Most of these agents are still in experimental stage though levodopa-carbidopa combination therapy has been widely studied in human amblyopes with good outcomes.

Although occlusion of the dominant eye is the best treatment modality for amblyopia, its efficacy decreases after 6 years of age. That's why, levodopa/carbidopa has been explored as an adjunct to conventional therapy and has been shown to have an immediate impact on VA; especially, in older age group, several studies to date have shown mixed results on the benefit of supplementing occlusion therapy with levodopa/carbidopa, although they have primarily studied children.

Levodopa may be considered as an adjunct to conventional occlusion therapy in cases with residual amblyopia and in older age group. Regression of effect after stoppage of therapy and occlusion amblyopia in younger patients (≤8 years) remain matters of concern. Further studies are therefore needed to evaluate the full efficacy and side effect profile of these agents.

Financial support and sponsorship

Nil.

Conflicts of interest

The authors have no any conflicts of interest to declare.

 
  References Top

1.
von Noorden GK, Campos EC. Binocular Vision and Ocular Motility: Theory and Management of Strabismus. 6th ed.. St. Louis: Mosby; 1990.  Back to cited text no. 1
    
2.
Hillis A, Flynn JT, Hawkins BS. The evolving concept of amblyopia: A challenge to epidemiologists. Am J Epidemiol 1983;118:192-205.  Back to cited text no. 2
    
3.
Noorden GK. Mechanisms of amblyopia. Adv Ophthalmol 1977;34:93-115.  Back to cited text no. 3
    
4.
Cotter SA; Pediatric Eye Disease Investigator Group, Edwards AR, Wallace DK, Beck RW, Arnold RW, Astle WF, et al. Treatment of anisometropic amblyopia in children with refractive correction. Ophthalmology 2006;113:895-903.  Back to cited text no. 4
    
5.
Chen PL, Chen JT, Tai MC, Fu JJ, Chang CC, Lu DW. Anisometropic amblyopia treated with spectacle correction alone: Possible factors predicting success and time to start patching. Am J Ophthalmol 2007;143:54-60.  Back to cited text no. 5
    
6.
Stewart CE, Moseley MJ, Fielder AR, Stephens DA; MOTAS Cooperative. Refractive adaptation in amblyopia: Quantification of effect and implications for practice. Br J Ophthalmol 2004;88:1552-6.  Back to cited text no. 6
    
7.
Cotter SA, Edwards AR, Arnold RW, Astle WF, Barnhardt CN, Beck RW, et al. Treatment of strabismic amblyopia with refractive correction. Am J Ophthalmol 2007;143:1060-3.  Back to cited text no. 7
    
8.
Scheiman MM, Hertle RW, Beck RW, Edwards AR, Birch E, Cotter SA, et al. Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol 2005;123:437-47.  Back to cited text no. 8
    
9.
Cleary M. Efficacy of occlusion for strabismic amblyopia: Can an optimal duration be identified? Br J Ophthalmol 2000;84:572-8.  Back to cited text no. 9
    
10.
Flynn JT, Woodruff G, Thompson JR, Hiscox F, Feuer W, Schiffman J, et al. The therapy of amblyopia: An analysis comparing the results of amblyopia therapy utilizing two pooled data sets. Trans Am Ophthalmol Soc 1999;97:373-90.  Back to cited text no. 10
    
11.
Watson PG, Sanac AS, Pickering MS. A comparison of various methods of treatment of amblyopia. A block study. Trans Ophthalmol Soc U K 1985;104(Pt 3):319-28.  Back to cited text no. 11
    
12.
Olson RJ, Scott WE. A practical approach to occlusion therapy for amblyopia. Semin Ophthalmol 1997;12:161-5.  Back to cited text no. 12
    
13.
Elder MJ. Occlusion therapy for strabismic amblyopia. Aust N Z J Ophthalmol 1994;22:187-91.  Back to cited text no. 13
    
14.
Hiscox F, Strong N, Thompson JR, Minshull C, Woodruff G. Occlusion for amblyopia: A comprehensive survey of outcome. Eye (Lond) 1992;6(Pt 3):300-4.  Back to cited text no. 14
    
15.
Woodruff G, Hiscox F, Thompson JR, Smith LK. Factors affecting the outcome of children treated for amblyopia. Eye (Lond) 1994;8(Pt 6):627-31.  Back to cited text no. 15
    
16.
Pediatric Eye Disease Investigator Group. The course of moderate amblyopia treated with patching in children: Experience of the amblyopia treatment study. Am J Ophthalmol 2003;136:620-9.  Back to cited text no. 16
    
17.
Scott WE, Kutschke PJ, Keech RV, Pfeifer WL, Nichols B, Zhang L. Amblyopia treatment outcomes. J AAPOS 2005;9:107-11.  Back to cited text no. 17
    
18.
Dorey SE, Adams GG, Lee JP, Sloper JJ. Intensive occlusion therapy for amblyopia. Br J Ophthalmol 2001;85:310-3.  Back to cited text no. 18
    
19.
Hug T. Full-time occlusion compared to part-time occlusion for the treatment of amblyopia. Optometry 2004;75:241-4.  Back to cited text no. 19
    
20.
Pediatric Eye Disease Investigator Group. A randomized trial of patching regimens for treatment of moderate amblyopia in children. Arch Ophthalmol 2003;121:603-11.  Back to cited text no. 20
    
21.
Pediatric Eye Disease Investigator Group. A randomized trial of prescribed patching regimens for treatment of severe amblyopia in children. Ophthalmology 2003;10:2075-87.  Back to cited text no. 21
    
22.
Ron A, Nawratzki I. Penalization treatment of amblyopia: A follow-up study of two years in older children. J Pediatr Ophthalmol Strabismus 1982;19:137-9.  Back to cited text no. 22
    
23.
Worth CA. Squint: Its Causes, Pathology and Treatment. Philadelphia Blakiston: Book Contributor: University of California Library; 1906.  Back to cited text no. 23
    
24.
Moseley MJ, Neufeld M, McCarry B, Charnock A, McNamara R, Rice T, et al. Remediation of refractive amblyopia by optical correction alone. Ophthalmic Physiol Opt 2002;22:296-9.  Back to cited text no. 24
    
25.
Foley-Nolan A, McCann A, O'Keefe M. Atropine penalisation versus occlusion as the primary treatment for amblyopia. Br J Ophthalmol 1997;81:54-7.  Back to cited text no. 25
    
26.
Simons K, Stein L, Sener EC, Vitale S, Guyton DL. Full-time atropine, intermittent atropine, and optical penalization and binocular outcome in treatment of strabismic amblyopia. Ophthalmology 1997;104:2143-55.  Back to cited text no. 26
    
27.
Repka MX, Ray JM. The efficacy of optical and pharmacological penalization. Ophthalmology 1993;100:769-74.  Back to cited text no. 27
    
28.
Pediatric Eye Disease Investigator Group. The course of moderate amblyopia treated with atropine in children: Experience of the amblyopia treatment study. Am J Ophthalmol 2003;136:630-9.  Back to cited text no. 28
    
29.
Pediatric Eye Disease Investigator Group. A randomized trial of atropine regimens for treatment of moderate amblyopia in children. Ophthalmology 2004;111:2076-85.  Back to cited text no. 29
    
30.
Tejedor J, Ogallar C. Comparative efficacy of penalization methods in moderate to mild amblyopia. Am J Ophthalmol 2008;145:562-9.  Back to cited text no. 30
    
31.
von Noorden GK, Attiah F. Alternating penalization in the prevention of amblyopia recurrence. Am J Ophthalmol 1986;102:473-5.  Back to cited text no. 31
    
32.
Pediatric Eye Disease Investigator Group. Pharmacological plus optical penalization treatment for amblyopia: Results of a randomized trial. Arch Ophthalmol 2009;127:22-30.  Back to cited text no. 32
    
33.
Bietti GB, Scorsonelli M. Effects of oxygen on the suppression phenomena during binocular vision in strabismus. Riv Med Aeronaut 1955;18:23-67.  Back to cited text no. 33
    
34.
Barany E, Hallden U. Experiments aiming at the treatment of squint amblyopia with medicaments. Acta Ophthalmol (Copenh) 1949;27:138.  Back to cited text no. 34
    
35.
Pettigrew JD, Kasamatsu T. Local perfusion of noradrenaline maintains visual cortical plasticity. Nature 1978;271:761-3.  Back to cited text no. 35
    
36.
Duffy FH, Burchfiel JL, Snodgrass SR. The pharmacology of amblyopia. Ophthalmology 1978;85:489-95.  Back to cited text no. 36
    
37.
Domenici L, Cellerino A, Maffei L. Monocular deprivation effects in the rat visual cortex and lateral geniculate nucleus are prevented by nerve growth factor (NGF). II. Lateral geniculate nucleus. Proc Biol Sci 1993;251:25-31.  Back to cited text no. 37
    
38.
Leguire LE, Rogers GL, Bremer DL, Walson P, Hadjiconstantinou-Neff M. Levodopa and childhood amblyopia. J Pediatr Ophthalmol Strabismus 1992;29:290-8.  Back to cited text no. 38
    
39.
Leguire LE, Rogers GL, Walson PD, Bremer DL, McGregor ML. Occlusion and levodopa-carbidopa treatment for childhood amblyopia. J AAPOS 1998;2:257-64.  Back to cited text no. 39
    
40.
Leguire LE, Rogers GL, Bremer DL, Walson PD, McGregor ML. Levodopa/carbidopa for childhood amblyopia. Invest Ophthalmol Vis Sci 1993;34:3090-5.  Back to cited text no. 40
    
41.
Leguire LE, Walson PD, Rogers GL, Bremer DL, McGregor ML. Longitudinal study of levodopa/carbidopa for childhood amblyopia. J Pediatr Ophthalmol Strabismus 1993;30:354-60.  Back to cited text no. 41
    
42.
Dadeya S, Vats P, Malik KP. Levodopa/carbidopa in the treatment of amblyopia. J Pediatr Ophthalmol Strabismus 2009;46:87-90.  Back to cited text no. 42
    
43.
Pediatric Eye Disease Investigator Group, Repka MX, Kraker RT, Dean TW, Beck RW, Siatkowski RM, et al. A randomized trial of levodopa as treatment for residual amblyopia in older children. Ophthalmology 2015;122:874-81.  Back to cited text no. 43
    
44.
Pediatric Eye Disease Investigator Group. Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol 2005;123:437-47.  Back to cited text no. 44
    
45.
Pediatric Eye Disease Investigator Group. Two-year follow-up of a 6-month randomized trial of atropine vs patching for treatment of moderate amblyopia in children. Arch Ophthalmol 2005;123:149-57.  Back to cited text no. 45
    
46.
Pediatric Eye Disease Investigator Group. Patching vs atropine to treat amblyopia in children aged 7 to 12 years: A randomized trial. Arch Ophthalmol 2008;126:1634-42.  Back to cited text no. 46
    
47.
Rogers GL. Functional magnetic resonance imaging (fMRI) and effects of L-DOPA on visual function in normal and amblyopic subjects. Trans Am Ophthalmol Soc 2003;101:401-15.  Back to cited text no. 47
    
48.
Kasamatsu T, Pettigrew JD, Ary M. Restoration of visual cortical plasticity by local microperfusion of norepinephrine. J Comp Neurol 1979;185:163-81.  Back to cited text no. 48
    
49.
Kasamatsu T, Pettigrew JD. Preservation of binocularity after monocular deprivation in the striate cortex of kittens treated with 6-hydroxydopamine. J Comp Neurol 1979;185:139-61.  Back to cited text no. 49
    
50.
Imamura K, Kasamatsu T. Interaction of noradrenergic and cholinergic systems in regulation of ocular dominance plasticity. Neurosci Res 1989;6:519-36.  Back to cited text no. 50
    
51.
Leguire LE, Walson PD, Rogers GL, Bremer DL, McGregor ML. Longitudinal study of levodopa/carbidopa for childhood amblyopia. J Pediatr Ophthalmol Strabismus 1993;30:354-60.  Back to cited text no. 51
    
52.
Rashad MA. Pharmacological enhancement of treatment for amblyopia. Clin Ophthalmol 2012;6:409-16.  Back to cited text no. 52
    
53.
Brandies R, Yehuda S. The possible role of retinal dopaminergic system in visual performance. Neurosci Biobehav Rev 2008;32:611-56.  Back to cited text no. 53
    
54.
Yeh KC, August TF, Bush DF, Lasseter KC, Musson DG, Schwartz S, et al. Pharmacokinetics and bioavailability of Sinemet CR: A summary of human studies. Neurology 1989;39 11 Suppl 2:25-38.  Back to cited text no. 54
    
55.
Basmak H, Yildirim N, Erdinç O, Yurdakul S, Ozdemir G. Effect of levodopa therapy on visual evoked potentials and visual acuity in amblyopia. Ophthalmologica 1999;213:110-3.  Back to cited text no. 55
    
56.
Gottlob I, Charlier J, Reinecke RD. Visual acuities and scotomas after one week levodopa administration in human amblyopia. Invest Ophthalmol Vis Sci 1992;33:2722-8.  Back to cited text no. 56
    
57.
Leguire LE, Komaromy KL, Nairus TM, Rogers GL. Long-term follow-up of L-dopa treatment in children with amblyopia. J Pediatr Ophthalmol Strabismus 2002;39:326-30.  Back to cited text no. 57
    
58.
Mohan K, Dhankar V, Sharma A. Visual acuities after levodopa administration in amblyopia. J Pediatr Ophthalmol Strabismus 2001;38:62-7.  Back to cited text no. 58
    
59.
Procianoy E, Fuchs FD, Procianoy L, Procianoy F. The effect of increasing doses of levodopa on children with strabismic amblyopia. J AAPOS 1999;3:337-40.  Back to cited text no. 59
    
60.
Leguire LE, Walson PD, Rogers GL, Bremer DL, McGregor ML. Levodopa/carbidopa treatment for amblyopia in older children. J Pediatr Ophthalmol Strabismus 1995;32:143-51.  Back to cited text no. 60
    
61.
Jaeb Center for Health Research. Levodopa for the Treatment of Residual Amblyopia (ATS17). Bethesda, MD: US National Library of Medicine; 2010. Available from: http://www. ClinicalTrials.gov. [Last updated on 2016 May 03].  Back to cited text no. 61
    
62.
Zhou JH, Liu CY, Zhang RH, Wang HR, Liu KJ. Effects of octreotide on gallbladder pressure and myoelectric activity of Oddi sphincter in rabbits. World J Gastroenterol 1998;4:238-241.  Back to cited text no. 62
    
63.
Orge FH, Dar SA. Visual acuity improvement of amblyopia in an adult with levodopa/carbidopa treatment. J Pediatr Ophthalmol Strabismus 2015;52:e45-7.  Back to cited text no. 63
    
64.
Repka MX, Kraker RT, Beck RW, Atkinson CS, Bacal DA, Bremer DL, et al. Pilot study of levodopa dose as treatment for residual amblyopia in children aged 8 years to younger than 18 years. Arch Ophthalmol 2010;128:1215-7.  Back to cited text no. 64
    
65.
Nahata MC, Morosco RS, Leguire LE. Development of two stable oral suspensions of levodopa-carbidopa for children with amblyopia. J Pediatr Ophthalmol Strabismus 2000;37:333-7.  Back to cited text no. 65
    
66.
Kothari M. Occlusion-amblyopia following high dose oral levodopa combined with part time patching. Indian J Ophthalmol 2014;62:1163-5.  Back to cited text no. 66
[PUBMED]  [Full text]  
67.
Li R, Liang T, Li Y, Jiang W, Huang R. Effects of l-dopa methyl ester on visual cortex injury induced by amblyopia and its underlying mechanism. Neurosci Lett 2012;508:95-100.  Back to cited text no. 67
    
68.
Zhao KX, Shi XF. Progress in research of strabismus and amblyopia in China in the new century. Zhonghua Yan Ke Za Zhi 2005;41:729-35.  Back to cited text no. 68
    
69.
Yang YF, Sun HJ, Hu YD. Effect of NMDA receptor in visual development. Yanke Xin Jinzhan 2005;25:378-80.  Back to cited text no. 69
    
70.
Yin Z, Yu T, Chen L. Electron microscopic analysis of expression of NMDA-R1 in the developmental process of visual cortex in strabismic amblyopic cat. Zhonghua Yan Ke Za Zhi 2002;38:472-5.  Back to cited text no. 70
    
71.
Shao LG, Guo JQ, Li TY. Experimental studies on expression of N-methy-D-aspartate recepor-1-subunit in area 17 of the visual cortex in MS and MD kittens during the critical period. Chin J Optom Ophthalmol 2002;4:211-4.  Back to cited text no. 71
    
72.
Sun XN, Zhang JS. Influences of levodopa on expression of N-methyl-D-aspartate receptor-1-subunit in the visual cortex of monocular deprivation rats. Int J Ophthalmol 2012;5:50-4.  Back to cited text no. 72
    
73.
Den D, Long S, Mai G, Wu DZ, Chen G. Effect of levodopa on visual evoked potential in amblyopia. Yan Ke Xue Bao 1997;13:182-5.  Back to cited text no. 73
    
74.
Gottlob I, Wizov SS, Reinecke RD. Visual acuities and scotomas after 3 weeks' levodopa administration in adult amblyopia. Graefes Arch Clin Exp Ophthalmol 1995;233:407-13.  Back to cited text no. 74
    
75.
Algaze A, Roberts C, Leguire L, Schmalbrock P, Rogers G. Functional magnetic resonance imaging as a tool for investigating amblyopia in the human visual cortex: A pilot study. J AAPOS 2002;6:300-8.  Back to cited text no. 75
    
76.
Guest PC, Knowles MR, Molon-Noblot S, Salim K, Smith D, Murray F, et al. Mechanisms of action of the antidepressants fluoxetine and the substance P antagonist L-000760735 are associated with altered neurofilaments and synaptic remodeling. Brain Res 2004;1002:1-10.  Back to cited text no. 76
    
77.
Maya Vetencourt JF, Sale A, Viegi A, Baroncelli L, De Pasquale R, O'Leary OF, et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 2008;320:385-8.  Back to cited text no. 77
    
78.
Duffy FH, Burchfiel JL, Mower GD, Joy RM, Snodgrass SR. Comparative pharmacological effects on visual cortical neurons in monocularly deprived cats. Brain Res 1985;339:257-64.  Back to cited text no. 78
    
79.
Burchfiel JL, Duffy FH. Role of intracortical inhibition in deprivation amblyopia: Reversal by microiontophoretic bicuculline. Brain Res 1981;206:479-84.  Back to cited text no. 79
    
80.
Mower GD, Christen WG, Burchfiel JL, Duffy FH. Microiontophoretic bicuculline restores binocular responses to visual cortical neurons in strabismic cats. Brain Res 1984;309:168-72.  Back to cited text no. 80
    
81.
Secades JJ, Lorenzo JL. Citicoline: Pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol 2006;28 Suppl B:1-56.  Back to cited text no. 81
    
82.
Porciatti V, Schiavi C, Benedetti P, Baldi A, Campos EC. Cytidine-5'-diphosphocholine improves visual acuity, contrast sensitivity and visually-evoked potentials of amblyopic subjects. Curr Eye Res 1998;17:141-8.  Back to cited text no. 82
    
83.
Campos EC, Schiavi C, Benedetti P, Bolzani R, Porciatti V. Effect of citicoline on visual acuity in amblyopia: Preliminary results. Graefes Arch Clin Exp Ophthalmol 1995;233:307-12.  Back to cited text no. 83
    



 
 
    Tables

  [Table 1]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Pharmacological ...
Conclusion
References
Article Tables

 Article Access Statistics
    Viewed303    
    Printed9    
    Emailed0    
    PDF Downloaded79    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]